// our company

Our Management Team

eTheRNA is managed by an experienced team of committed biotech professionals.
A team dedicated to bringing eTheRNA’s mRNA-based TriMix technology to the next level.

Steven Powell

CEO

Steven Powell

Steven has acquired broad experience in several life-science sectors in R&D, corporate finance and commercial roles. He started his career with Beecham Pharmaceuticals (now GSK) and subsequently held senior roles with both public and private biotechnology and healthcare companies in Europe and North America. He was also a partner with a European venture capital fund.

Bernard Sagaert

VP Manufacturing

Bernard Sagaert

Bernard is an industrial pharmacist and licensed Qualified Person with extensive and broad experience in the Pharmaceutical industry internationally in large, medium sized and small companies.

Diane Van Hoorick

Group Project Director

Diane Van Hoorick

Diane is a molecular biophysicist with over 10 years of experience in pharmaceutical R&D; from drug discovery to clinical development. Before joining eTheRNA, Diane held the position of Head of immune oncology project management at Ablynx, Sanofi.

Dirk Van Broekhoven

VP Corporate Management, General Counsel

Dirk Van Broekhoven

Dirk has more than twenty-five years of experience as legal counsel in the healthcare industry. In addition to his general legal, he has specialized in intellectual property management and corporate development and licensing.

Korden Walter

Director Preclinical Development

Korden Walter

Korden is a tumor virologist by training and has over 10 years’ experience in non-clinical drug development in oncology and neurological disease indications. He has worked in both biotech and pharmaceutical industry.

Marina Cools

VP Clinical Development

Marina Cools

Marina is a virologist with over twenty years of experience in pharmaceutical R&D; from drug discovery to late stage clinical development. She has worked with biotech SMEs and large pharmaceutical companies.

Stefaan De Koker

Non-Clinical Principal Scientist, Site Director Ghent

Stefaan De Koker

Stefaan is Principal Scientist with over 15 years of research experience in immunology, immuno-oncology, vaccine design and nucleic acid delivery. He has a publication track record of over >50 publications and is the key author of a number of patents.

Ulrich Platte

CFO

Ulrich Platte

Ulrich has over 20 years experience in a number of different industrial sectors including the life science, medical device and pharmaceutical sectors. He has held senior positions in financial management roles, including previous CFO roles.

Beatrice De Vos

CMO (interim)

Beatrice De Vos

Beatrice is a physician specialized in pharmaceutical medicine. For the past 30 years she has worked in leading positions in clinical research departments of pharmaceutical companies. As advisor to biotech and pharma companies, she is currently involved in developing advanced therapy medicinal products and immunotherapies.
// our company

A Strong
Shareholder Base

eTheRNA’s shareholders are all highly renowned investors
in the life science sector.
Since its inception, eTheRNA has raised a total amount of over EUR 30 million in equity investments and non-dilutive funding, including
a Series A financing of EUR 24 million announced early 2016.
That was one of the largest private investment rounds for a start-up biotechnology company in Belgium, and even Europe.
// our company

Our Board of Directors

eTheRNA is managed by an experienced team of committed biotech professionals.
Who will bring eTheRNA’s mRNA-based TriMix technology to the next level.
Russel G. Greig
Chairman of the Board
Alexandra Tolia
Representing Fund+
Frank Kalkbrenner
Representing BIV Fund
John de Koning
Representing LSP
Kenneth Wils
Representing PMV
Steven Powell
CEO
Vincent Brichard
External Industry Expert
Vincent Ossipow
Representing Omega Funds

Galileilaan 19, 2845 Niel, Belgium

Our Address

Our Mailbox

+32 3 369 17 40

Our Phone

© 2020 Etherna | Studio Hanswijk